Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics has announced the first patient dosing in a Phase 1/2 clinical trial for its novel CDH17-directed CAR-T cell therapy, aimed at treating advanced gastrointestinal cancers. This significant step marks the beginning of a trial designed to establish a recommended dose and assess the therapy’s safety and effectiveness. The innovative treatment, developed at the University of Pennsylvania, has shown promise in preclinical studies by eradicating tumors in various cancer models without harming normal tissues.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
